{"data":{"id":"us-in/ic-16-42-23-8","jurisdiction":"us-in","citation":"IC 16-42-23-8","heading":"Federal funding of health care facilities","body":"Sec. 8. If:\n(1) the federal government indicates that the federal government will withdraw all federal funds from a health care facility for allowing amygdalin (laetrile) to be used within the facility; and\n(2) providing or allowing use of amygdalin (laetrile) within the facility would jeopardize the receipt of:\n(A) federal funds for reimbursement for Medicare or Medicaid for all persons within the facility; or\n(B) construction funds provided by the federal government under the Hill-Burton Hospital Construction Program (42 U.S.C. 291 et seq.) or under Title XVI of the Public Health Services Act (42 U.S.C. 300q-300t);\nthe hospital or other health care facility may prohibit the use of amygdalin (laetrile) within the hospital or facility.","path":["TITLE 16. HEALTH","ARTICLE 42. REGULATION OF FOOD, DRUGS, AND COSMETICS","Chapter 23. Drugs: Use of Amygdalin (Laetrile)"],"source_url":"https://iga.in.gov/ic/2026/Title_16.html#16-42-23-8","current_through":"2026","vintage":"2026","retrieved_at":"2026-09-11T20:02:18Z","sha256":"6a2435e341e8fe0847b8ac15c33362cc4ef7e431f027187f969609c765c37c11","source_id":"us-in","stale":false,"prev":"us-in/ic-16-42-23-7","next":"us-in/ic-16-42-24-1"},"notice":"GroundRules: Original legal text. Not legal advice."}